IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 40.098
AS - Asia 4.008
NA - Nord America 2.824
Continente sconosciuto - Info sul continente non disponibili 711
SA - Sud America 327
AF - Africa 68
OC - Oceania 1
Totale 48.037
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 39.387
US - Stati Uniti d'America 2.619
SG - Singapore 1.727
CN - Cina 1.063
VN - Vietnam 546
FR - Francia 327
BD - Bangladesh 321
BR - Brasile 207
HK - Hong Kong 122
FI - Finlandia 114
DE - Germania 66
CA - Canada 65
AR - Argentina 56
JP - Giappone 53
MX - Messico 46
GB - Regno Unito 44
IN - India 28
JM - Giamaica 25
CH - Svizzera 23
ES - Italia 23
IQ - Iraq 22
ID - Indonesia 21
CR - Costa Rica 20
NL - Olanda 18
VE - Venezuela 15
RU - Federazione Russa 14
EC - Ecuador 13
PL - Polonia 13
IE - Irlanda 12
PH - Filippine 12
ZA - Sudafrica 11
CO - Colombia 10
HN - Honduras 10
MA - Marocco 10
UA - Ucraina 10
PE - Perù 9
SE - Svezia 9
DZ - Algeria 8
GT - Guatemala 8
JO - Giordania 8
SA - Arabia Saudita 8
TH - Thailandia 8
NI - Nicaragua 7
PK - Pakistan 7
AZ - Azerbaigian 6
CL - Cile 6
PY - Paraguay 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
KE - Kenya 5
TR - Turchia 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
KZ - Kazakistan 4
LT - Lituania 4
RO - Romania 4
RS - Serbia 4
SN - Senegal 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
UZ - Uzbekistan 4
BH - Bahrain 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
IR - Iran 3
KR - Corea 3
LB - Libano 3
MY - Malesia 3
NP - Nepal 3
PR - Porto Rico 3
SI - Slovenia 3
TN - Tunisia 3
AF - Afghanistan, Repubblica islamica di 2
AT - Austria 2
BB - Barbados 2
BE - Belgio 2
BW - Botswana 2
CI - Costa d'Avorio 2
EG - Egitto 2
GA - Gabon 2
KW - Kuwait 2
LV - Lettonia 2
MM - Myanmar 2
MU - Mauritius 2
NO - Norvegia 2
OM - Oman 2
RE - Reunion 2
SC - Seychelles 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CZ - Repubblica Ceca 1
Totale 47.305
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Genoa 8.192
Rapallo 3.374
Vado Ligure 2.245
Singapore 826
San Jose 658
Lauterbourg 317
Ashburn 271
Ho Chi Minh City 165
New York 139
Beijing 135
Hanoi 127
Helsinki 114
Hong Kong 114
Santa Clara 77
Bordighera 65
Los Angeles 56
Frankfurt am Main 51
Tokyo 44
Council Bluffs 43
Chicago 33
Dallas 30
Milan 28
Tianjin 27
Buffalo 26
Mexico City 25
Rome 24
São Paulo 24
Philadelphia 21
Zurich 20
Haiphong 19
Naples 19
Orem 17
Atlanta 16
Guangzhou 16
Las Vegas 16
San José 16
Charlotte 14
City of London 13
Houston 13
Kingston 13
Biên Hòa 12
Da Nang 12
Miami 12
Montreal 12
Newark 12
Orlando 12
Phoenix 12
Toronto 12
Queens 11
San Francisco 11
Seattle 11
Dublin 10
Hải Dương 10
Amsterdam 9
Brooklyn 9
Cleveland 9
Detroit 9
Rio de Janeiro 9
Washington 9
Boston 8
Cardiff 8
Jakarta 8
Shanghai 8
Stockholm 8
Warsaw 8
Amman 7
Curitiba 7
El Paso 7
Louisville 7
Madrid 7
Managua 7
Porto Alegre 7
Turin 7
Arroyo Grande 6
Bangkok 6
Boardman 6
Bologna 6
Bắc Ninh 6
Can Tho 6
Chennai 6
Chula Vista 6
Garland 6
Guatemala City 6
London 6
Portland 6
San Salvador 6
Shenzhen 6
The Bronx 6
Vĩnh Long 6
Baghdad 5
Bowie 5
Buenos Aires 5
Columbus 5
Denver 5
Greenville 5
Manchester 5
Milwaukee 5
Minneapolis 5
Mumbai 5
Totale 43.156
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 310
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 257
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 233
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 232
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 219
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 217
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 214
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 209
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 209
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 208
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 208
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 207
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 204
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 202
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 200
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 197
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 197
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 197
Apalutamide treatment and metastasis-free survival in prostate cancer 193
Management of young women with early breast cancer 192
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 190
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 190
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial 190
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 189
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 186
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 185
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 185
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 185
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 185
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. 184
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 183
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 181
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 181
Differential expression of nuclear lamins in normal and cancerous prostate tissues 180
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 180
Belagenpumatucel-L for the treatment of non-small cell lung cancer 180
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 179
Adjuvant chemotherapy of bladder cancer. 178
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 177
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 175
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 175
Immunotherapy for genitourinary cancer: State of the art and new perspectives 174
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 172
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 171
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 171
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 171
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 171
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with Radium-223: A proof of concept study 171
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 170
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 170
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 170
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 169
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 168
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. 167
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! 167
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 166
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 166
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 166
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 165
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 165
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 165
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 165
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 164
D-TRP-6-LH-RH treatment of advanced prostatic cancer 164
Bone metastases from prostate cancer: hormonal therapy 164
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 163
Combinations of hormonal therapy and chemotherapy 163
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis 162
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 161
Adjuvant therapy for patients with node negative breast cancer. 159
Ovarian ablation in early breast cancer: overview of the randomised trials. 159
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 159
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 159
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 158
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 158
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 156
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 156
Leiomyosarcoma of the broad ligament: a case report and review of literature. 155
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 155
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 155
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 154
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 154
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 153
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 153
Switching to aromatase inhibitors in early breast cancer. 153
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 152
Use of metronomic chemotherapy in oncology: results from a national Italian survey. 152
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 152
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 152
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 151
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 151
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 151
Nafarelin acetate and benign prostatic hyperplasia. 150
Oral vinorelbine in the treatment of non-small-cell lung cancer. 150
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. 149
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 149
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. 149
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. 149
An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients 149
Presence and distribution of growth factors in breast cyst fluid. 148
Totale 17.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.060
article - articoli 134.944
book - libri 704
conference - conferenze 302
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 14.110
Totale 300.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.214 105 289 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/20255.476 130 458 218 402 719 539 482 884 223 262 470 689
2025/20269.687 1.031 311 661 742 1.274 1.067 1.641 429 603 911 599 418
2026/20271.051 1.051 0 0 0 0 0 0 0 0 0 0 0
Totale 48.037